Radient Pharmaceuticals Corporation fka RXPC

[GetSeriousOK]

I've been reading QuantRx's SEC filings...

Looks to me like QTXB is a zombie biotech that basically does nothing but sit around and pay a couple of officer salaries and possibly pay a lease on a brick-and-mortar office.

I don't think there's much chance that QTXB will buy the Radient Pharmaceuticals carcass from the Aussies. But we can hope!

QuantRx has nothing to sell. Their balance sheet shows ZERO revenues. Their burn rate is only about $80,000 per quarter.... meaning they are doing little or nothing with their "PadKit," whatever THAT is.

Their A/S is 150 million and the O/S is around 68 million. Not a whole lot of room for dilution, but once they merge, I bet they increase the A/S and hype a 510(k) for the lung cancer test -- and sell shares to fund the adventure.

Here is the latest 10-Q from QuantRx

http://www.sec.gov/Archives/edgar/data/820608/000141588915003757/qtxb10q_sep302015.htm

"If [the merger is] executed, the Company [QuantRX] will acquire 100% of the outstanding capital stock of Global in exchange for restricted shares of the Company's common stock..."

That means anyone who bought GCDX stock from Willie gets restricted shares of QTXB. Ahhh the irony... the Merger Theorists claimed to be personal friends of Willie but they were 100% wrong about GCDX and Radient merging... they should have been buying GCDX shares instead of RXPC!

"Pursuant to the terms and conditions of the Global LOI, the Company advanced to Global $50,000 during the quarter ended September 30, 2015 (the "Global Advance"), which amount is due and payable by Global, on demand, anytime after the Termination Date. In the event the Company and Global execute definitive merger documents on or before the Termination Date, Global will issue to the Company that number of shares of Global's common stock equal to 10% of the then outstanding shares of Global's common stock, on a fully-diluted basis as payment of the Global Advance. "

Yes, GCDX is that badly in need of $50,000! I guess DR-70 isn't selling so well on the internet?

In summary.... QTXB has about $1.7M in debt with no money coming in.... and GCDx needed $50,000 from QTXB.... we have a couple of BIOTECH TITANS here. This will be a huge opportunity for our Radient Merger Theorists, who seem to love to throw money at anything that involves Gartner.